Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75 mg twice daily administration

Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75 mg twice daily administration

Abstract Background Dabigatran is a direct thrombin inhibitor and an anticoagulant that is prescribed to prevent ischemic stroke and systemic embolism in non-valvular atrial fibrillation. Dabigatran (150 mg twice daily) is non-inferior to warfarin for the prevention of stroke and systemic embolism....

Full description

Bibliographic Details
Main Authors: Yuuki Akagi, Tatsuo Chiba, Shusuke Uekusa, Hiroyoshi Kato, Shigeo Yamamura, Yukiko Aoki, Mizuho Enoki, Yuka Ogawara, Takanori Kasahara, Yuki Kimura, Tadahiro Shimizu, Aiko Takeishi, Yuko Nakajima, Hideki Kobayashi, Kaoru Sugi
Format: Article
Language:English
Published: BMC 2019-08-01
Series:Journal of Pharmaceutical Health Care and Sciences
Subjects:
Dabigatran
Anticoagulant
Excessive dose reduction
Thromboembolism
Non-valvular atrial fibrillation
Retrospective study
Online Access:http://link.springer.com/article/10.1186/s40780-019-0145-3

Internet

http://link.springer.com/article/10.1186/s40780-019-0145-3

Similar Items